








1149-17 Six-Month Results of Stenting Following Cutting 
Balloon Angioplasty in Small Coronary Arteries: A 
Randomized Comparison With Stenting Following 
Conventional Balloon Angloplasty 
Hiseshi Umeda. Toru Tajika, Yosuke Murase, Toshikazu Tanaka, Hirohumi Kanda, Ken 
Sawada, Maseki Yamauch], Hirokazu Iwata, Hitoshi Ishihara, Mitsuhiro Yokota, Mitsunori 
Iwase, Gifu Shakaihoken Hospital, Kani, Japan, Okazaki City Hospital, Okazaki, Japan. 
Background: The outcomes of patients with coronary angioplasty in small coronary 
artedes were unfavorable. Recent reports have shown that cutting balloon angioplasty 
(CBA) was achieved favorable 6-month results in small vessels, and suggested that CBA 
may cause less tissue injury and vessel stretch, producing an efficient arterial lumen 
compared to conventional balloon angioplasty (POBA). The purpose of this study was to 
evaluate 6-month outcomes of CBA followed by stenting in small coronary arteries. 
Methods: Study subjects consisted of 147 lesions of 126 patients with the reference 
diameters of target vessels <2.8 ram, who were enrolled and randomized to stanting fol- 
lowing CBA (CBA-stant: 74 lesions; 64 Pt.) or POBA (POBA-stent: 73 lesions; 62 Pt.). 
Intravascular ultrasound was performed at post-procedure and 6-month follow up. 
Results: The clinical and lesion characteristics were similar in both groups. Initial suc- 
cess rate were similar in both groups (CBA-stent: 95%, POBA-stent: 97%). 4 lesions in 
CBA-stent crossed over to POBA-stent because of the inability to reach the lesion. There 
were no differences in stent type, stent size, stant length, numbers of stents, and maxi- 
mum inflation pressure between 2 groups. 
6-month follow-up results 
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CBA-stent POBA-stent p value 
Ref, diameter (mm) 2,4±0.4 2.5±0.3 ns 
Acute gain (mm) 1.8±0.3 1.8±0.5 ns 
Late loss (mm) 0.8±0.5 1.0±0,6 0.04 
Net gain (mm) 1,0±0.5 0.6±0,7 0.06 
Neointima (mm2) 2.2±1.1 2.8±2.0 0.03 
6-month TLR (%) 13 27 0.03 
6-month MACE (%) 14 29 0.04 
TLR= target lesion revascularization; MACE= major adverse cardiac event (Death, MI, 
and TLR) 
Conclusions: 6-month results of slanting following CBA were favorable due to less 
naointimsl hyperplasia, suggesting that slanting following CBA were more effective in 
cases with small coronary arteries compared to conventional balloon angioplasty fol- 
lowed by stenting. 
1149-18 Effect of Baseline Thrombus in the SAFER (Saphenous 
Vein Graft Angioplasty Free of Emboll Randomized) 
Trial 
Satvendra Gid, Richard E. Kuntz, Andrew C. Eisenhauer, Jeffrey J. Popma, Ross Prpic, 
Unsal Kaya, Campbell Rogers, Donald S. Bairn, Brigham & Women's Hospital, Boston, 
Massachusetts, Harvard Clinical Research Institute, Boston, Massachusetts. 
BACKGROUND: Saphanous vein graft (SVG) lesions with angiographic thrombus (A't) 
are at increased risk for distal embolization. METHODS: To determine the impact of AT 
on major adverse cardiac event (MACE= death, MI, or revasculadzation) and distal pro- 
tection using the PercuSurge GuardWire TM system we evaluated patients with (n=298) 
and without (n=463) ATenrollecl in the SAFER trial using quantitative coronary angiogra- 
phy. RESULTS: Pts with ATwere slightly older (69~10 vs 68+10, p=0.04), and had more 
rest angina (44.6% vs 35.3%, p<0.01 ) but had similar demographic and comorbidity pro- 
file. ATpts had larger reference vessel diameter (3.54-+0.67 vs 3.34 _+0,66, p<0.01 ), more 
residual % stenosis (16+13 vs 13¢11, p=0.008) and angiographic flow-relatad complica- 
tions (reduced or no-reflow, 12.9% vs 5.3%, p=<0.001). This included no-reflow (9.9% vs 
3.4%, p<0,001), worsening of TIMI antegrade flow (4.2% vs 1 0%, p<0.01), distal embo- 
lization (3.6% vs 2.0%, p=0.18), and prolonged final frame-to-opaclfication count 
(28.7+_21 vs 24.7_+14, p=0.002) compared to non-ATpts. 
AT pts had more 30-day MACE (17.4% vs 10.4%, p=0.006), death (3.0% vs 0.9%, 
p=0.04), MI (15.8% vs 9.1%, p=0.006) but similar target lesion revascularization (2.0% vs 
1.3%, p=0.55). GuardWire m use reduced the flow-related complications in the subset of 
thrombus-laden SVG lesions (see Table).CONCLUSlON: PCI in thrombotic SVG lesions 
had higher rates of flow-related and clinical complications, which was reduced by the use 
of PercuSurga GuardWire 1M 
Multivariate predictor Odds Ratio 95% C.I. p value 
Angiogrephic omplication 5.299 2.855 - 9.837 0.001 
Persistent hrombus 2.732 1.406 - 5.3111 0.001 
Lesion length(mini 1,032 1.014- 1.050 0.01 
Final % diameter stenosis 1.019 1.001 - 1.036 0.04 
GuardWirs Use 0.624 0.392 - 0.994 0.02 
1149-19 Impact of Thrombus Removal on Myocardial 
Reparfusion in PsUents With Acute Myocardial 
Infarction Treated With Primary StenUng 
Eulooio Gamia. Joseph Ludwig, Raul Moreno, Leopoldo Perez Isla, Alicia Barrio, Manuel 
Abeytua, Javier Soriano, Carlos Crespo, Amalia Mota, Marina Paz, Hospital Gregorio 
Maranon, Madrid, Spain. 
Final TIMI flow is clearly correlated with outcome in patients with AIM who undergo 
mechanical raperfusion. Nevertheless, full epicardial flow does not necessarily correlates 
with appropiate myocardial reperfusion. Angiographic suggestion of addecuate myocar- 
dial reperfusion is being locked as one of the most appropiate markers of effective treat- 
ment and dessirable clinical outcome. 
In order to determine the influence of thrombus removal to obtain adequate myocardial 
reperfusion, we have analised the influence of TIMI 3 flow ad myocardial blush score in 
50 patients with AMt of less than 6 hours from the onset of symptoms (ca/diogehic shock 
excluded) and who underwent mechanical repeffusion with the use of the X-Sixer device 
followed bu stent implantationl These results ware compared with those of 200 matched 
by infarct size and clinical profile who underwent mechanical repedusion with stant 
implantation without prior thrombus aspiration. The quantitative angiographic analyis, 
TIMI flow and myocardial blush score are listed betow. 
X-Sizer plus stent Stent p 
Pre-procedure 
RVD (ram) 3,1 (SD 0.47) 3.13 (SD 0.45) NS 
MLD (mm) 0.24 (SD 0.45) 0.26 (SD 0.43) NS 
% DS 91 (SD 14) 92 (SD 13) NS 
TIMI O-1 (%) 74 78 NS 
Post-procedure 
RVD (mm) 3.21 (SD 0.43) 3.32 (SD 0.47) NS 
MLD (ram) 2.74 (SD 0.45) 2.76 (SD 0.52) NS 
% DS 14.5 (SD 7.6) 13 (SD 8.5) NS 
TIMI 3 (%) 97 95.4 NS 
Myocardial blush 3 (%) 55 28 <0.01 
Conclusion: Compared to stent implantation, thrombus aspiration followed by stent in 
patients with AMI is associated with similar classical angiographic results and TIMI 3 
flow, but better myocardial blush 3 score, that suggests more adequate myocardial perfu- 
sion. 
1149-20 HOW Rapidly and Durably Are Platelets Inhibited by a 
300 mg Clopidogrel Loading Dose Given at the Time of 
Intervention Compared to Loading Before Intervention? 
Paul A. Gurbel, Alex I. Malinin, Kevin P. Callahan, Michele J. Buczkowski, Victor L. 
Serebruany, Sinai Hospital, Baltimore, Maryland. 
BACKGROUND: The affect of a 300 mg loading dose of ctopidogrel administered in the 
catheterization laboratory at the time of coronary stanting versus pratreatment on the 
kinetics of platalet inhibition is unknown.METHODS: Patients undergoing elective stent- 
ing (n=103) were treated with either 300 mg clopidogrel at the time of the procedure (TP) 
or at 3-6 (3-6 pre) or 24 hours (24 pre) prior to the procedure. Platelet-rich plasma aggre- 
gation (PPA) (5p mol ADP), and flow cytometry of platelet receptors were serially per- 
formed. All patients received 325 mg aspirin and 75 mg clopidogrel daily post procedure. 
GP lib/Ilia inhibitors were not used. RESULTS: PPA was most inhibited at 2 and 24 
hours post-stenting by loading 24 hours prior to the procedure (p<.05) (see table). PAC-1 
(mean fluorescence intensity) was mildly reduced by clopidogrel (78 ± 46, baseline, 62 +- 
40, day 5, p<O.05). No effect was seen on platelet-leukocyte aggregate formation.CON- 
CLUSION: Pretreatment with 300 mg clopidogre124 hours prior to intervention gives the 
best early post procedure inhibition of ADP-induced platelet aggregation. Loading with 
clopidogrel followed by 75 mg daily mildly reduces activation of GPIIb/llla but does not 
affect the formation of platelet-leukocyte aggregates. 
PPA (%Inhibition) 
Time of assessment TP 3-6 pre 24 pre 
2h post 14± 4 18+ 7 35+ 15" 
24 h post 35_+ 11 33± 16 47_+ 23* 
5d post 31_+ 13 41-+ 12 41-+ 14 
* p<.05 compared to TP and 3 - 6 pre 
1149-21 In-Vivo Evaluation of a Novel ePTFE-Covered Self- 
Expanding Slant for  the Treatment of Diseased 
Saphenous Vein Bypass Grafts 
Steohen Oestede, Charles Davidson, Richard Kuntz, Craig Nordhausen, Michael 
Vonesh, Mark UIm, Nicholas Macri, Massachusetts Genera/Hospital, Boston, 
Massachusetts. 
Background: There has been continued interest in covered stents for use in degenerative 
saphenous vein grafts (SVGs), but restenosis rates have been less than ideal. We evalu- 
ated long, ePTFE-covered, self-expanding stants in a porcine model. 
Methods: 80 devices (46ram-long; 4, 4.5 or 5ram-diameter) were implanted bilaterally in 
the common carotid (CCA) and internal mammary artedes (IMA) of 22 miniswina. Typi- 
cally, 4mm devices were implanted in the IMA and 5mm devices in the CCA. Device 
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oversizing was recorded at implant. Paired vessels were implanted with 1 Heparin- 
Coated (HC) and 1 Non-Coated (NC) device. 4 in-life periods were evaluated: 1-week 
(5); 4-week (7); 12-week (5); 24-week (5). Animals received ASA (350rag/d) and clopi- 
dogrel (75mg/d). Angiography was performed at 1, 2, 4, and every 4.weeks thereafter 
including retrieval. In-stant percent diameter stenosis (%DS) was quantified and histopa- 
thology performed at retrieval. 
Results: 41 NC and 39 HC devices were evaluated. CCA implants remained widely 
patent, with 24-week animals remaining in-life at the time of this abstract. Occlusion 
occurred in 4 IMA devices (2 HC; 2 NC) at 8-weeks and in 1 IMA device (t HC) at 12- 
weeks. Probability of patency was equivalent for HC and NC devices. All devices exhib- 
ited a benign histological response. The luminal surfaces of NC devices were extensively 
to diffusely covered by fibrous connective tissue, with good incorporation into the ePTFE 
and multifosel "endothelial-like" cells. HC devices exhibited reduced tissue coverage, 
with luminal surfaces devoid of cellular material or multifocally covered by thin fibrous 
connective tissue. A significant difference in device oversizing was noted for IMA (25%) 
as compared to CCA implants (10%). This corresponds to an 8-week %DS of 67% in IMA 
devices as compared to only 21% in CCA implants. 
Conclusions: (1) CCA implants were widely patent with evidence of endothelialization, (2) 
excessive IMA device oversizing may be associated with increased %DS and higher 
occlusion rates, and (3) HC devices exhibited reduced neointimal coverage. These 
results support initiation of a clinical feasibility tnal to establish the safety of this ePTFE- 
covered device in degenerative SVGs. 
1149-22 Impact  of  Stent Length on Reatenosis Rate in Smal l  
Vessels 
Konstantinos Toutouzas, Goran Stankovic, Takuro Takagi, Vassilis Spanos, Carlo Di 
Mado, Remo Albiero, Nicola Corvaja, Alaide Chieffo, Ginevra Sivied, Antonio Colombo, 
Centro Cuore Columbus, Milan, Italy. 
Stent implantation in smafl coronary vessels is associated with an increased rate of rest- 
enosis. The aim of this study was to examine the influence of stent length on clinical and 
angiographic outcome in patients (pts) with lesions in small vessels. Methods. On the 
basis of pre-procedural angiography 459 pts with 536 lesions in small vessels with refer- 
ence diameter < 2.8 mm treated with stents were included in the study. Major adverse 
cardiovascular events (MACE) were defined as: death, myocardial infarction (MI) and tar- 
get lesion revascuiarization (TLR). Results. The incidence of in-hospital MACE was 
4.3%. Death was encountered in 2 pts (0.4%) and MI in 13 pts (2.8%). In 5 pts Q wave 
and in 8 pts non-Q-wave MI was observed. Subacuta thrombosis was observed in 6 pts 
(1.3%). At clinical follow-up (mean duration: 10.32 ± 12.34 months) 76% of the pts were 
free of MACE. The TLR rate was 23%. Angiogrephic follow-up was accomplished in 60% 
of the pts and the restenosis rate was 41.3%. Multivariate analysis showed that slant 
length was the strongest predictor for angiographic restenosis (odds ratio: 1.041, 95% 
C.I. 1.02 - 1.06, p < 0~01). The correlation between stent length and relative risk (RR) for 
restenosis is shown (fig). There is a 4% increment in the risk for restenosis for 1 mm 
increment in stent length. Conclusions. In small vessels implantation of long stents is 
accompanied by increased incidence of restenosis Thus, long lesions in small vessels 
provide a challenging substrata for emerging antirestenotic therapies. 
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1150-6 P-Select in  Neut ra l i za t ion  P revents  Neo in t ima l  
Formation in e Diabetic Rat Model 
Zhonamin Zhou. Kai Wang, Farhad Forudi, Xiaorong Zhou, Khaldoun Tarakji, Marc S. 
Penn, A. Michael Lincoff, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Enhanced inflammatory response to vascular injury is an important feature of increased 
restenosis in diabetes. P-selectin has been shown to play a key role in mediating inflam- 
mation by promoting adherence of leukocytes to activated platelets and endothelium.By 
using a recombinant soluble form of P-selectin Glycoprotain LIgand-1 (rPSGL-Ig) as a 
competitive inhibitor for the natural ligand, the effect of P-selectin blockade on neointimal 
formation was investigated in a Zuckar diabetic rat carotid artery balloon injury model. 
Method and Result: 38 male Zuckar diabetic rats underwent balloon injury to the left 
carotid artery. Animals were randomly assigned to either rPSGL-Ig (lmg/kg IV) or saline 
administration at 30 minutes before balloon injury. 24 animals were sacrificed at 1,3, and 
7 days after balloon injury, P-selectin neutralization was determined by immunohis- 
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tochemistry. The remaining 14 rats were sacdficed at 21 days. Morphomethc analysis 
was performed, rPSGL-Ig m~rkedly reduced neointimal area (0.03 ± 0.01 mm 2 vs 0.12 _+ 
0.02 mm 2, p< 0.01) and neointima/media ratio (0.40 + 0.15 vs 1.21 + 0.23, p<0.05). 
Immunohistochemistry showed e significant decrease in the presence of P.selectin in the 
injured carotid arteries in the rPSGL-Ig group at day 1, 3, and 7. Conclusion: P-selectin 
blockade using rPSGL-Ig potently reduces neointimal formation in a diabetic rat model, 
by neutralization of P-selectin expression, rPSGL-Ig may have potential for preventing of 
restenosis in diabetes. 
1150-7 Serum Levels of  Inter leukin-1 ~ Converting Enzyme/ 
Caspase-1 Can Be Used to Detect and Quantify 
Apoptotic Process in Patients With Coronary Artery 
Disease Undergoing Percutaneous Transluminal 
Coronary Ang iop laaty  
Emanuel V. Economou. Christos Pitsevos, Anastasia Katinioti, Atl~anasios Tdkas, Marina 
Toutouza, Christodoulo~ Stetanadis, Pavlos Toutouzas, Dept. CardioL, Univ. Athens, 
Hippokration Hospital, Athens, Greece. 
Interleukin-t ~ converting enzyme / caspase-1 (ICE) is strongly implicated to many of the 
proteolytic events dudog atherosclerosis promoter apoptosis, and in this context, is 
recently accepted as an indicator for activation of this process. Aim of the study was to 
clarify if ICE levels can detect and quantify any apoptotic process evoked by acute vas- 
cular endothelial damage-related percutaneous transluminal coronary aogioplasty 
(PTCA). Methods : 38 patients (pts) with 1-vessel (20/38), and 2-vessel (18/38) coronary 
artery disease (CAD) underwent pdmary successful, uncomplicated PTCA. 20 CAD pts 
who underwent coronary angiography without PTCA (CA) and 20 healthy subjects (HS) 
served as controls. Peripheral blood was sampled at baseline before and 24 hours (h) 
after PTCA or CA and 3 and 6 months (m) after PTCA and was evaluated for ICE serum 
levels. Results : PTCA and CA pts with 2-vessel CAD both presented ICE levels higher 
than the respective levels of those with 1-vessel CAD (PTCA : 124±9.4 vs 30.2±4.1 pg/ 
mL and CA : 115±7.8 vs 35.7±5.6 pg/mL, p<0.001 in both cases). Moreover, at beseline 
PTCA pts presented ICE levels similar to those of CA pts (66.1±3.7 vs 65.3±2.9 pg/mL, 
p=NS) but higher than those of HS (16.8±1.5 pg/mL, p<0.001). After PTCA, ICE levels 
gradually declined at all the interval times assessed (24h after : 61.9±1.9 pg/mL, 3m after 
: 39.2±5.4 pg/mL, 6m after : 24.2±4.1 pg/m/, p<0.02 in all cases compared with both the 
corresponding value of the previous interval assessing time and to HS levels). No other 
changes in ICE levels were noticed after PTCA or CA at all the interval times assessed in 
comparison to the corresponding levels before the respective procedure. Conclusions : 
CAD appears to be associated with apoptosis which can be identified and quantified by 
measuring ICE serum levels. However, PTCA does not evoke such an apoptotic process. 
Instead, it gradually decreases apoptosis identified and quantified by ICE serum levels, 
to values slightly higher than those of healthy subjects. Since, serum levels of ICE are 
associated with the severity of CAD, local stenosis may stimulate this apoptotic process 
and thus, revascularization resulted from PTCA may be responsible for its significant 
decrease. 
1150-8 Dif ferent ia l  Effect of Coronary Stenting on Endogenous 
Vascu lar  Endothe l ia l  Growth  Factor  Production 
Hossam El Gendi. Julian Smith, Balvinder Wasan, Rajdeep Khattar, Azza Hussein, 
Rodney Foale, Jamil Mayet, Cardiology Department, St mary's Hospital, London, United 
Kingdom. 
Introduction: Intrecoronary administration of Vascular Endothelial Growth Factor (VEGF) 
has been explored as means of increasing cotlateralisation in patients with end-stage 
coronary artery disease. However, to date no study has examined the effect of stent 
implantation on endogenous VEGF production. The aim of this study was to examine 
local as well as systemic endogenous VEGF production in slanted vs non-stented 
patients during coronary intervention. 
Method: VEGF level was prospectively examined in 16 patients (8 stented) undergoing 
left coronary system intervention. Coronary sinus and peripheral samples were obtained 
at baseline, immediately after intervention and 24 hours later. Blood samples were centri- 
fuged and plasma separated for further analysis. The level of VEGF was then determined 
using an enzyme-linked immunosorbent assay (ELISA) (R&D systems UK). 
Results: Both groups of patients have experienced a significant drop in VEGF level 
immediately following the intervention compared with baseline level, both in the non- 
stented group{ peripherally (89.8± 26.6 vs 118.8±20.1 p=0.03) and locally 110.4±20.4 vs 
129±20, p=0.01)} and in the stented group {peripherally (111.3¢ 26.6 vs 133.6±25.6 
p=0.01) and locally 106.38±26.4 vs 121.88±27.4, p=0.01)}. However, after 24 hours 
there was a rebound increase in VEGF in non stented patients, while VEGF level contin- 
ued to drop in stented patients (220.38±32.3 vs 77.63±16.4 p=0.002). 
Conclusion: Coronary stenting is associated with superior vessel patancy compared with 
coronary angioplasty alone, this in turn confers greater perfusion to the previously 
ischaemic area and therefore damp the hypoxic stimulus for VEGF production. The use 
of VEGF coated stents may therefore augment the lower endogenous levels and thereby 
accelerate reendothelialization. 
